UPDATE: Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $35 at Canaccord Genuity

(updated to add analyst comment)

Canaccord Genuity analyst John Newman raised the price target on Aldeyra Therapeutics (NASDAQ: ALDX) to a 'Street High' $35.00 (from $27.00) while maintaining a Buy rating.

The analyst comments "We are maintaining our BUY rating and raising our NPV-derived price target to $35 from $27, based on our expectation for positive Phase 3 dry eye data given the statistically significant improvement across all selected symptom and signs metrics seen in Phase 2b. Furthermore, we continue to expect positive Phase 3 data in allergic conjunctivitis YE18/early 2019, and also positive Phase 3 data in SLS and anterior noninfectious uveitis in 2019."

You May Also Be Interested In

• JPMorgan Starts Kanzhun Ltd (2076:HK) at Overweight
• Veru sets up $21.8M at-the-market stock offering
• JPMorgan Upgrades Bajaj Housing Finance (BAJAJHFL:IN) to Neutral